Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386040897> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4386040897 endingPage "B12" @default.
- W4386040897 startingPage "B12" @default.
- W4386040897 abstract "Cutaneous immune-related adverse events (cirAEs) are the most common toxicities to occur in the setting of immune checkpoint inhibitor (ICI) therapy. Conventional treatments for cirAEs include topical and systemic steroids, and, less commonly, biologics. There is growing interest in understanding the impact of immunomodulating medications, including dupilumab, on clinical outcomes for ICI patients. Using data from Mass General Brigham, we identified 33 patients who received dupilumab after starting ICI treatment. Cohorts were propensity score-matched on age, sex, race/ethnicity, and ICI type. The time-varying multivariable Cox proportional hazards model was adjusted for ICI cycle, cirAE status, organ system, tissue type, systemic steroid use, and cancer stage. Among the study group, 82% of patients started dupilumab for treatment of their cirAEs, while 12% of patients were treated with dupilumab for flare of their pre-existing dermatoses after starting ICI. 6% of patients were treated with dupilumab for their asthma. The most common rash morphologies were eczematous (42%) and bullous (29%), followed by lichenoid (10%), psoriasiform (10%), isolated pruritus (6%), morbilliform (3%), morphea (3%), and sclerodermoid (3%). 74% of patients had significant improvement with dupilumab, while 10% had partial improvement. Multivariate modeling demonstrated that receiving dupilumab had no significant impact on survival for patients who received ICI (HR = 1.01, p-value > 0.9). Given the significant improvement in symptoms and lack of adverse impact on survival, there is evidence to support the use of dupilumab in patients experiencing cirAEs. Furthermore, this can likely allow patients to stay on ICI therapy for longer, optimize quality of life, and reduce the likelihood of treatment discontinuation due to cirAEs." @default.
- W4386040897 created "2023-08-22" @default.
- W4386040897 creator A5003959503 @default.
- W4386040897 creator A5012435050 @default.
- W4386040897 creator A5030482050 @default.
- W4386040897 creator A5055719391 @default.
- W4386040897 creator A5071349804 @default.
- W4386040897 creator A5078193406 @default.
- W4386040897 creator A5080093777 @default.
- W4386040897 date "2023-09-01" @default.
- W4386040897 modified "2023-10-14" @default.
- W4386040897 title "LB1686 Impact of dupilumab on survival in patients treated with immune checkpoint inhibitors" @default.
- W4386040897 doi "https://doi.org/10.1016/j.jid.2023.06.059" @default.
- W4386040897 hasPublicationYear "2023" @default.
- W4386040897 type Work @default.
- W4386040897 citedByCount "0" @default.
- W4386040897 crossrefType "journal-article" @default.
- W4386040897 hasAuthorship W4386040897A5003959503 @default.
- W4386040897 hasAuthorship W4386040897A5012435050 @default.
- W4386040897 hasAuthorship W4386040897A5030482050 @default.
- W4386040897 hasAuthorship W4386040897A5055719391 @default.
- W4386040897 hasAuthorship W4386040897A5071349804 @default.
- W4386040897 hasAuthorship W4386040897A5078193406 @default.
- W4386040897 hasAuthorship W4386040897A5080093777 @default.
- W4386040897 hasConcept C126322002 @default.
- W4386040897 hasConcept C143998085 @default.
- W4386040897 hasConcept C16005928 @default.
- W4386040897 hasConcept C197934379 @default.
- W4386040897 hasConcept C2776173921 @default.
- W4386040897 hasConcept C2778329239 @default.
- W4386040897 hasConcept C2778570526 @default.
- W4386040897 hasConcept C2779824493 @default.
- W4386040897 hasConcept C2780564577 @default.
- W4386040897 hasConcept C71924100 @default.
- W4386040897 hasConceptScore W4386040897C126322002 @default.
- W4386040897 hasConceptScore W4386040897C143998085 @default.
- W4386040897 hasConceptScore W4386040897C16005928 @default.
- W4386040897 hasConceptScore W4386040897C197934379 @default.
- W4386040897 hasConceptScore W4386040897C2776173921 @default.
- W4386040897 hasConceptScore W4386040897C2778329239 @default.
- W4386040897 hasConceptScore W4386040897C2778570526 @default.
- W4386040897 hasConceptScore W4386040897C2779824493 @default.
- W4386040897 hasConceptScore W4386040897C2780564577 @default.
- W4386040897 hasConceptScore W4386040897C71924100 @default.
- W4386040897 hasIssue "9" @default.
- W4386040897 hasLocation W43860408971 @default.
- W4386040897 hasOpenAccess W4386040897 @default.
- W4386040897 hasPrimaryLocation W43860408971 @default.
- W4386040897 hasRelatedWork W2408550297 @default.
- W4386040897 hasRelatedWork W2766528424 @default.
- W4386040897 hasRelatedWork W3167826726 @default.
- W4386040897 hasRelatedWork W3177720512 @default.
- W4386040897 hasRelatedWork W3180031743 @default.
- W4386040897 hasRelatedWork W3193570890 @default.
- W4386040897 hasRelatedWork W3204561650 @default.
- W4386040897 hasRelatedWork W4225834195 @default.
- W4386040897 hasRelatedWork W4237621822 @default.
- W4386040897 hasRelatedWork W4323567762 @default.
- W4386040897 hasVolume "143" @default.
- W4386040897 isParatext "false" @default.
- W4386040897 isRetracted "false" @default.
- W4386040897 workType "article" @default.